Should Baseline Laboratory Tests Be Ordered?
Yes, baseline laboratory tests should be ordered for children ≥10 years of age (or after puberty onset) with BMI ≥85th percentile who have risk factors including family history of diabetes, hypertension, dyslipidemia, or signs of insulin resistance. 1
Guideline-Based Screening Recommendations
The 2017 Endocrine Society Clinical Practice Guideline explicitly recommends that children or adolescents with a BMI ≥85th percentile be evaluated for potential comorbidities 1. This is a strong recommendation based on the substantial evidence that overweight and obese children face significant cardiometabolic risks.
Which Laboratory Tests to Order
For children meeting these criteria, the recommended screening panel includes:
- Fasting lipid panel (to detect dyslipidemia)
- Fasting glucose and/or hemoglobin A1C (to detect prediabetes or type 2 diabetes)
- Liver function tests (ALT/AST to screen for hepatic steatosis)
These tests should be performed every 2 years according to AAP guidelines 2.
Age and Risk Factor Considerations
Age threshold: Screening is recommended starting at ≥10 years of age or after puberty onset, whichever comes first. This timing is critical because insulin sensitivity physiologically decreases during puberty, increasing metabolic risk 3.
Risk factors that mandate screening include:
- Family history of type 2 diabetes in first- or second-degree relatives
- Signs of insulin resistance (acanthosis nigricans, PCOS)
- Maternal history of gestational diabetes
- Race/ethnicity with higher diabetes prevalence (Black, Hispanic, Native American, Asian American, Pacific Islander)
Evidence Supporting This Approach
Research demonstrates alarmingly high prevalence of metabolic complications in this population. One study found that among obese children, 43.8% had metabolic syndrome, 14.4% had impaired glucose tolerance, and 3.7% had type 2 diabetes 4. Another study showed that 70.5% had insulin resistance 4. These data underscore that metabolic complications are not rare but rather the norm in pediatric obesity with risk factors.
The Problem of Underscreening
Despite clear guidelines, only 27.3% of children with obesity receive recommended screening, with even lower rates (11.7%) when screening is ordered at well-child visits 2. This represents a critical gap in care that directly impacts early detection and intervention opportunities.
Fasting Insulin: A Complementary Marker
While not part of routine screening panels, fasting insulin provides complementary information to BMI for identifying children at highest cardiometabolic risk 5. Recent evidence shows fasting insulin demonstrates stronger associations with dyslipidemia and dysglycemia than BMI-SDS alone 5. Consider adding fasting insulin to your initial workup, particularly in children with severe obesity or multiple risk factors.
What NOT to Order
Do not routinely order thyroid function tests or insulin levels for endocrine causes of obesity unless the child has attenuated height velocity or short stature relative to genetic potential 1. Routine thyroid screening in obesity without growth concerns represents overuse—approximately 30% of children with obesity receive potentially unnecessary thyroid or insulin tests 2.
Clinical Pitfalls to Avoid
- Don't wait for symptoms: Type 2 diabetes and metabolic syndrome often develop silently in children
- Don't assume normal weight equals low risk: Approximately 25% of children with normal BMI may have excess body fat 1
- Don't screen children <10 years unless they have entered puberty or have extreme obesity with multiple risk factors
- Don't forget racial/ethnic variations: Asian and Hispanic children may have higher cardiometabolic risk at lower BMI thresholds 1